CSL (HAM:CSJ) PE Ratio: 97.47 (As of Jun. 24, 2026) — 149% Above Median


HAM:CSJ CSL Ltd HAM:CSJ
73 GF Score
Price €68.23
GF Value €170.71
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is CSL PE Ratio?

CSL HAM:CSJ +0.07% 73 PE Ratio is 97.47 as of Jun. 24, 2026, which is 149% above its 10-year median of 39.22. GuruFocus rates HAM:CSJ with a GF Score™ of 73/100 and a GF Value™ of €170.71 (Significantly Undervalued). The stock has 7 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-24), CSL's share price is €68.23. CSL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.70. Therefore, CSL's PE Ratio for today is 97.47.

During the past 13 years, CSL's highest PE Ratio was 94.26. The lowest was 10.19. And the median was 39.22.

CSL's EPS (Diluted) for the six months ended in Dec. 2025 was €0.70. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.70.

As of today (2026-06-24), CSL's share price is €68.23. CSL's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €3.07. Therefore, CSL's PE Ratio without NRI ratio for today is 22.23.

During the past 13 years, CSL's highest PE Ratio without NRI was 55.28. The lowest was 10.19. And the median was 39.22.

CSL's EPS without NRI for the six months ended in Dec. 2025 was €3.07. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €3.07.

During the past 12 months, CSL's average EPS without NRI Growth Rate was -33.70% per year. During the past 3 years, the average EPS without NRI Growth Rate was 11.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 6.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 9.70% per year.

During the past 13 years, CSL's highest 3-Year average EPS without NRI Growth Rate was 107.80% per year. The lowest was 0.10% per year. And the median was 13.85% per year.

CSL's EPS (Basic) for the six months ended in Dec. 2025 was €0.71. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.71.

Back to Basics: PE Ratio


CSL  (HAM:CSJ) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


CSL PE Ratio Related Terms


CSL PE Ratio Historical Data

* Premium members only.

The historical data trend for CSL's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSL PE Ratio Chart

CSL Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.85 39.39 41.09 35.97 25.27

CSL Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Jun25 Dec25
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.09 At Loss 35.97 25.27 At Loss

HAM:CSJ vs VRTX, REGN, ALNY: PE Ratio Comparison

For the Biotechnology subindustry, CSL's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CSL PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's PE Ratio distribution charts can be found below:

* The bar in red indicates where CSL's PE Ratio falls into.


HAM:CSJ
73GF Score
CSL Ltd HAM:CSJ
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSL PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

CSL's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=68.23/0.700
=97.47

CSL's Share Price of today is €68.23.
For company reported semi-annually, CSL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.70.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 97.47 mean?
CSL (HAM:CSJ) has a PE Ratio of 97.47 as of Jun. 24, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on CSL and its competitors. This is 149% above median its historical median of 39.22. Over the past decade, CSL's PE Ratio has ranged from 10.19 to 94.26.
Is CSL's PE Ratio too high?
CSL's current PE Ratio of 97.47 is 149% above median its 10-year median of 39.22. Over the past 10 years, this metric has ranged from a low of 10.19 to a high of 94.26. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's PE Ratio compare to VRTX and REGN?
CSL's PE Ratio of 97.47 can be compared against companies in the Biotechnology industry. Historically, CSL's own PE Ratio has ranged from 10.19 to 94.26 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Biotechnology company?
A good PE Ratio depends on the Biotechnology industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on CSL and its competitors. CSL's current PE Ratio is 97.47, which is 149% above median its own 10-year median of 39.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (HAM:CSJ) is currently considered Significantly Undervalued. The stock's GF Value™ is €170.71, compared to a current price of €68.23 — trading 60% below its estimated fair value. The current PE Ratio is 97.47, which is 149% above median its 10-year median of 39.22. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For CSL (HAM:CSJ), the current PE Ratio is 97.47 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSL (HAM:CSJ) Overvalued in 2026?

Based on GuruFocus' analysis, CSL stock appears to be undervalued. The current stock price of €68.23 is trading 60% below its estimated GF Value™ of €170.71. GuruFocus considers CSL to be Significantly Undervalued.

Key valuation signals for HAM:CSJ:

  • PE Ratio: 97.47 (149% above median its 10-year median of 39.22)
  • GF Value™: €170.71 vs. price of €68.23 (60% below fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the HAM:CSJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CSL Business Description

Address 655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score

Get the complete analysis for HAM:CSJ

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€68.23
Price
€170.71
GF Value